Best Immunology Companies in San Diego, United States
The 52 best Immunology companies in San Diego, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Mirador.
Ranked: Best Immunology companies in San Diego
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Mirador Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases 50Funding top 15%Growth top 35%Moat top 42%Tech top 44% All 9 signals ▾Fundingtop 15% Growthtop 35% Moattop 42% Techtop 44% Producttop 49% Talentbottom 49% Newsbottom 38% Globalbottom 36% Marketbottom 32% Funding: Raised $480M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $480M | 6 mo ago | Series B | — | Mark McKenna Founder & CEO | — | — |
| 2 | Sorrento Therapeutics Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases 67Funding top 20%Patents top 20%Market top 26%Moat top 30% All 12 signals ▾Fundingtop 20% Patentstop 20% Markettop 26% Moattop 30% Innovationtop 32% Growthtop 45% Fin. healthtop 45% Partnerstop 45% Talentbottom 49% Globalbottom 44% Techbottom 31% Newsbottom 27% Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $282M | 15 mo ago | Public | 949 | Henry Ji Co-Founder & CEO | 1,073 patents Targeted antibody-drug conjugates and resiniferatoxin-based therapies for cancer and neurodegeneration | — |
| 3 | Escient Pharmaceuticals Developer of small molecule based therapeutics for the treatment of inflammatory diseases | $238M | 44 mo ago | Acquired | 44 | — | — | — |
| 4 | Candid Therapeutics Developer of therapeutics for autoimmune diseases 40Funding top 17%Growth top 38%News top 48%Moat top 48% All 8 signals ▾Fundingtop 17% Growthtop 38% Newstop 48% Moattop 48% Talentbottom 49% Techbottom 38% Globalbottom 38% Marketbottom 32% Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $206M | 4 mo ago | Acquired | — | Ken Song CEO | — | — |
| 5 | Ambit Biosciences Biopharmaceutical company discovering and developing kinase inhibitor drugs for oncology and autoimmune… | $163M | 164 mo ago | Acquired | 55 | — | 423 patents Novel heterocyclic small‑molecule kinase inhibitors for oncology therapeutics | — |
| 6 | BioAtla Developer of immunotherapies for cancer using active biologics platform | $162M | 72 mo ago | Public | 41 41 → 35 (-15%) | Jay Short Chairman | 698 patents Therapeutic antibodies and engineered proteins for targeted cancer and aging cell treatments | — |
| 7 | Reneo Pharmaceuticals Development of the treatment for orphan diseases | $145M | 67 mo ago | Public | 48 | Gregory Flesher President & CEO | — | — |
| 8 | Aristea Therapeutics Developer of small molecule based therapeutics for inflammatory diseases | $118M | 60 mo ago | Deadpooled | 10 | James Mackay Founder & CEO | — | — |
| 9 | RayThera Developer of small molecule therapies for unmet needs in immunology | $110M | 15 mo ago | Series A | — | Gene Hung Co-Founder & CSO | 12 patents Small-molecule inhibitors of Jak2 V617F, TNF‑α, STAT6, and CCR4 signaling pathways | — |
| 10 | CalciMedica Developer of CRAC channel inhibitor drugs for inflammatory diseases | $87M | 15 mo ago | Public | 11 | — | 264 patents CRAC channel inhibitor therapeutics for inflammatory lung injury and pancreatitis | — |
| 11 | Kemia Discovers and develops small molecule therapeutics for autoimmune and cardiovascular diseases. | $84M | 239 mo ago | Deadpooled | — | Lewis Shuster CEO | 39 patents Cytokine inhibitor therapeutics and pharmaceutical compositions targeting inflammatory pathways | — |
| 12 | Fate Therapeutics Developer of cellular immuno-therapeutics for the treatment of cancer and immune disorders | $78M | 72 mo ago | Public | 181 181 → 227 (+25%) | Scott Wolchko President & CEO | 606 patents Patents concentrated in chemistry & materials | 2 job openings |
| 13 | Tr1X Developer of T cell-based products to treat autoimmune and inflammatory diseases | $75M | 15 mo ago | Series A | 7 | David Vries Co-Founder | 35 patents Engineered IL-10‑secreting CAR‑CD4+ T cell immunotherapies for cancer treatment | — |
| 14 | ARS Pharmaceuticals Developer of therapeutics for the treatment of allergic reactions | $75M | 58 mo ago | Public | 34 | Sarina T Co-Founder and Chief Medical Officer | — | — |
| 15 | Recludix Pharma Provider of the online platform for drug discovery and development | $60M | 56 mo ago | Series A | 33 33 → 54 (+64%) | Brian Hodous Co-Founder | — | — |
| 16 | Belharra Provider of photoaffinity-based chemoproteomics platform for drug discovery | $50M | 42 mo ago | Series A | 56 | Jeff Jonker CEO | — | — |
| 17 | Replicate Bioscience Developer of RNA-Based therapeutics for cancer treatment | $46M | 58 mo ago | Series A | 8 | Nathaniel Wang Chief Executive Officer and Co-Founder | 115 patents Engineered cytokine biologics and self-replicating mRNA therapeutics for disease treatment | — |
| 18 | Receptos Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $36M | 173 mo ago | Acquired | 68 | — | 254 patents Sphingosine‑1‑phosphate receptor modulators for autoimmune disease therapeutics | 1 partnership |
| 19 | PVP Biologics Developing novel therapeutics to reduce the burden of living with celiac disease | $35M | 114 mo ago | Acquired | 9 | David Baker Co-Founder | — | — |
| 20 | Equillium Developer of therapies for treating autoimmune and inflammatory disorders | $30M | 11 mo ago | Public | 36 36 → 38 (+6%) | Daniel Bradbury Co-Founder & CEO | 33 patents CD6‑targeted antibody therapeutics for autoimmune and inflammatory diseases | — |
| 21 | Adamis Pharmaceuticals Developer of therapeutics for treating respiratory disease and allergy | $16M | 77 mo ago | Public | 15 | — | 140 patents Injection devices and drug delivery formulations for emergency and therapeutic applications | — |
| 22 | SelectION Provider of screening and development platform for drugs 11Funding top 36%Talent bottom 49%Global bottom 37%Market bottom 17% All 4 signals ▾Fundingtop 36% Talentbottom 49% Globalbottom 37% Marketbottom 17% Funding: Raised $15.9M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $16M | 10 mo ago | Series A | 2 | Andreas Klostermann Founder & CSO | — | — |
| 23 | Amira Pharmaceuticals Discovery and early development of new drugs to treat inflammatory and fibrotic disease | $14M | 232 mo ago | Acquired | 25 | Bob Baltera CEO | 492 patents Design and synthesis of polycyclic small‑molecule LPA1 receptor antagonists for therapeutics | — |
| 24 | Abintus Developer of in vivo immune cell therapy | $14M | 47 mo ago | Series B | 13 | Carlos Ibanez Founder | — | — |
| 25 | Proprius Pharma Personalized medicine solutions in rheumatology and other autoimmune diseases. | $11M | 234 mo ago | Deadpooled | — | — | — | — |
| 26 | Thyritope Biosciences Therapeutics targeting thyroid stimulating auto-antibodies for the treatment of autoimmune diseases. | $10M | 142 mo ago | Deadpooled | — | David Campbell Founder | — | — |
| 27 | NovoMedix Early-stage Biopharma company developing orally-available small molecule drugs for fibrosis-related… | $9M | 18 mo ago | Funding Raised | 4 | Cathy Swindlehurst Founder & CEO | 56 patents Small-molecule biaryl sulfonamide drugs for treating pulmonary fibrosis | — |
| 28 | Luxvitae Therapeutics Developer of therapeutics for multiple diseases | $8M | 20 mo ago | Series A | — | Mathew Patt Founder | — | — |
| 29 | Gyre Therapeutics Developer of anti-fibrotic therapeutics for a variety of chronic organ diseases | $5M | 32 mo ago | Public | — | Han Ying CEO | — | — |
| 30 | Tega Therapeutics Glycoscience company developing heparan sulfate therapies and enzyme replacement therapy | $4M | 8 mo ago | Funding Raised | 7 | — | — | — |
| 31 | Femta Pharmaceuticals Develops therapeutic monoclonal antibodies | $4M | 189 mo ago | Deadpooled | — | Stephen Keane CEO | — | — |
| 32 | OrPro Therapeutics Developing biologic drug platform for lung diseases and epithelial surface treatments | $4M | 100 mo ago | Seed | 3 | Peter Heifetz Chief Executive Officer | — | — |
| 33 | Peptide Logic Provider of peptide therapeutics | $3M | 81 mo ago | Deadpooled | 11 | Pierre Riviere Founder & CEO | — | — |
| 34 | Carolus Therapeutics Drugs for patients suffering from acute and chronic inflammation | $2M | 160 mo ago | Early Stage | — | — | — | — |
| 35 | Cell IDx Advancing cancer diagnostics and improving lives through innovative solutions | $1M | 55 mo ago | Acquired | 7 | — | — | — |
| 36 | Arcturus Therapeutics Developer of RNAi technologies for the treatment of rare orphan diseases | $1M | 34 mo ago | Public | 337 | — | 488 patents Lipid nanoparticle formulations for RNA/mRNA delivery and vaccine therapeutics | 1 partnership |
| 37 | Divacs Developing cell-based immunotherapies for Type 1 Diabetes and SARS-CoV2 | $850K | 120 mo ago | Seed | — | Alan Lewis CEO | — | — |
| 38 | IGE Pharmaceuticals Company developing vaccines to treat allergies | $804K | 204 mo ago | Deadpooled | — | Swey Chen Founder & CEO | — | — |
| 39 | Animantis Next-gen computer vision for single-cell analysis, enabling better treatments | $550K | 90 mo ago | Seed | 3 | Ryan Kerwin Co-Founder/Chief Technology Officer | 5 patents Diagnostic tools for measuring immune system activity and therapy effectiveness | — |
| 40 | Consortia Therapeutics Developer of microbial therapies to treat food allergies enhancing the human gut microbiome | $432K | 96 mo ago | Deadpooled | — | Kent Smith Founder & CEO | — | — |
| 41 | Elgia Therapeutics Provider of therapeutics for the treatment of chronic inflammatory and fibrotic diseases | $288K | 33 mo ago | Seed | 6 | Adam Renslo Co-Founder | — | — |
| 42 | Venomyx Developing humanized antivenom. | $250K | 58 mo ago | Seed | 1 | Daniel Dempsey CEO and Founder | 3 patents Antivenom therapeutics and formulations for treating snakebite envenomation. | — |
| 43 | Blacksmith Medicines Developer of therapeutics for immuno-oncology and inflammatory diseases | $150K | 66 mo ago | Seed | 11 | Seth Cohen Co-Founder | 36 patents Discovery of antibacterial small‑molecule agents, especially LpxC enzyme inhibitors for Gram‑negative infections. | — |
Top 12 Immunology companies in San Diego
#1
Series B · San Diego, California · founded 2023$480Mraised▾
Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases. The company’s Mirador360 precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
- Jan 2026Series B$250M
- Feb 2024Series A$400M
- Dec 2023Seed$80M
#2
Acquired · San Diego, California · founded 2024$206.2Mraised▾
Developer of therapeutics for autoimmune diseases. It focuses on identifying and targeting specific pathways to develop therapies which include CND106 a bispecific antibody that targets and eliminate later stage B-cellsf or autoantibody disease treatment, CND261 targets a broad range of B-cell subtypes for autoimmune diseases.
- Mar 2026Series E$505M
- Sep 2024Series D$370M
#3
Public · San Diego, California · founded 1989 · 949 employees$281.6Mraised▾
Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases. The company’s lead products are multiple biosimilars and bio better antibodies as well as clinical CAR-T therapies targeting solid tumors. Also, has a portfolio of immuno-oncology antibody programs targeting EGFR, TNF-alpha, CD 25, and IGE. Its lead CAR-T cell therapies are against the carcinoembryonic antigen and prostate-specific membrane antigen.
- Apr 2025Post IPO$47.4M
- Sep 2018Conventional Debt—
- Jun 2018Post IPO$150M
- Nov 2016Venture Debt$50M
#4
Public · San Diego, California · founded 2006 · 11 employees$87Mraised▾
Developer of CRAC channel inhibitor drugs for inflammatory diseases. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications.
- Apr 2025Venture Debt$32.5M
- Apr 2023Post IPO$10.3M
- May 2020Series C$17.2M
- Sep 2014Grant (prize money)$145.5K
#5
Series A · San Diego, California · founded 2023$110Mraised▾
Developer of small molecule therapies for unmet needs in immunology. This company specializes in advancing drug discovery, leveraging proven expertise to accelerate the development process while maintaining rigorous standards. The focus is on creating transformative therapies to improve patient care. Their approach centers on developing breakthrough small molecule treatments addressing critical unmet needs within the immunology field.
- Apr 2025Series A$110M
#6
Series A · San Diego, California · founded 2018 · 7 employees$75Mraised▾
Developer of T cell-based products to treat autoimmune and inflammatory diseases. The Company uses its proprietary platform for the generation of cell therapy products to restore immune tolerance, with the potential to treat autoimmune and inflammatory diseases.
- Apr 2025Grant (prize money)$8M
- 2024Grant (prize money)$4M
- Jan 2024Series A$75M
#7
Public · San Diego, California · founded 2017 · 36 employees$30Mraised▾
Developer of therapies for treating autoimmune and inflammatory disorders. The lead product, itolizumab is a treatment for multiple severe immuno-inflammatory disorders, including graft-versus-host disease, uncontrolled moderate to severe asthma, and SLE / lupus nephritis.
- Aug 2025Post IPO$30M
#8
Series A · San Diego, California · founded 2017 · 2 employees$15.9Mraised▾
selectION provides screening and development platform for drugs. The company provides ion channel blockers by targeting additional potassium, sodium, calcium, and chloride channels, which will lead to other clinical applications in pain management and oncology. The company uses peptide structures derived from evolutionary tuned toxins from venomous animals like scorpions or cone snails as blueprints for its screening platform.
- Sep 2025Series A$20M
- Jun 2023Series A$11.8M
- May 2019Series A$4.1M
#9
Funding Raised · San Diego, California · founded 2013 · 7 employees$4.1Mraised▾
Glycoscience company developing heparan sulfate therapies and enzyme replacement therapy. Specializing in glycans, the company focuses on exploiting glycoscience-related technologies for treating life-threatening diseases. The company's pipeline includes recombinant production of heparan sulfate and enzyme replacement therapy to address genetic deficiencies in heparan sulfate degradation. They are dedicated to advancing the understanding and application of complex carbohydrates in medicine, aiming to unlock the therapeutic potential of glycans. This innovative approach positions them at the forefront of glycoscience, offering hope for novel treatments in areas with unmet medical needs.
- Nov 2025Grant (prize money)$500K
- Feb 2024Grant (prize money)$355.2K
- Sep 2023Grant (prize money)$461.7K
- Feb 2022Grant (prize money)$321.9K
#10
Funding Raised · San Diego, California · founded 2001 · 4 employees$8.7Mraised▾
NovoMedix is an early-stage Biopharma company developing orally-available small molecule drugs for fibrosis-related conditions. The company has been awarded 5 grants from SBIR for a total value of $3.5M. The most important grant is of $2M for the development of an anti-fibrotic drug for Triple Negative Breast Cancer. in Apr.2016, it received an SBIR grant for the development of a series of small molecule drug candidates for heart failure.
- Jan 2025Grant (prize money)$2M
- Sep 2024Grant (prize money)$306.9K
- Sep 2024Grant (prize money)$500K
- May 2022Grant (prize money)$2M
#11
Series A · San Diego, California · founded 2017$8.5Mraised▾
Developer of therapeutics for multiple diseases. It offers precision bioengineering technology for developing biologics like ADCs and monoclonal antibodies for cancer and auto-immune disease.
- Nov 2024Series A$8.5M
#12
Acquired · San Diego, California · founded 2017 · 44 employees$237.5Mraised▾
Developer of small molecule based therapeutics for the treatment of inflammatory diseases. It has developed the G protein-coupled receptor targeted drugs for the treatment of a broad range of neuro-immuno-inflammatory and autoreactive diseases.
- Nov 2022Series C$120M
- Sep 2020Series B$77.5M
- May 2018Series A$40M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in the United States
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,913 United States-affiliated papers.
- Dana-Farber Cancer Institute608
- The University of Texas MD Anderson Cancer Center559
- Harvard University524
- Cornell University416
- Brigham and Women's Hospital408
- Immune system88→1414
- Tumor microenvironment30→481
- Cancer41→483
- Cancer immunotherapy35→460
- T cell23→340
- Immune system205→2094
- Cancer86→884
- Oncology71→760
- Internal medicine109→672
- Tumor microenvironment72→632
- Immune system67→663
- Cancer40→389
- Oncology24→257
- Disease16→242
- Clinical trial11→209
Where immunology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in the United States
United States immunology patent filing is accelerating — 10,389 filings from 4,528 assignees (2016–2025), led by UNIV California, Memorial Sloan Kettering Cancer , US Health; annual filings 785→970.
- UNIV California399
- Memorial Sloan Kettering Cancer 350
- US Health315
- UNIV Texas296
- Iovance Biotherapeutics284
- Abbvie270
- UNIV Pennsylvania237
- DANA Farber Cancer INST222
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.